bioRxivCancer BiologyPreprint
SMAD4 MH2 Mutations Disrupt CREBBP/EP300 Recruitment and TGF-β-Induced Transcription in Colorectal Cancer
Md Saiful Islam, Sheikh NizamuddiniD, Timothy En Haw ChaniD, Omid FotouhiiD, Stefanie Koidl, H. T. Marc TimmersiD
Abstract
SMAD4 is a central transcriptional effector of the TGF-{beta} signaling pathway and a frequently inactivated tumor suppressor gene in various cancers. Missense mutations in its MH2 domain are among the most prevalent somatic alterations in colorectal cancer (CRC). These mutations are associated with disease progression and poor prognosis, yet their precise mechanistic consequences have remained incompletely characterized. Here, we show that CRC-derived SMAD4 MH2 hotspot mutations (D351H, S357P, R361C, and R361H) selectively impair co-activator recruitment without disrupting chromatin occupancy. RNA-seq profiling demonstrated broad suppression of TGF-{beta} target gene expression across all mutants. Notably, the mutations confer distinct degrees of TGF-{beta} pathway unresponsiveness: R361H is completely refractory to TGF-{beta} stimulation, whereas R361C and S357P retain partial transcriptional responsiveness suggesting allele-specific differences in the severity of co-activator interface disruption. Genome-wide chromatin binding analysis by greenCUT&RUN confirmed that all mutants maintain wild-type-like genomic occupancy, as expected given that the MH1 DNA-binding domain is intact in each case. Proximity-dependent biotinylation mass spectrometry in COLO205 cells revealed that all four mutants exhibit markedly reduced interactions with the CREBBP/EP300 histone acetyltransferase complex and BRD4 relative to wild-type SMAD4 identifying disrupted co-activator engagement. Collectively, our findings establish that SMAD4 MH2 mutations impair TGF-{beta}-induced transcription by selectively reducing CREBBP/EP300 recruitment, which provides a molecular mechanism for the loss-of-function SMAD4 phenotype in CRC. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=154 SRC="FIGDIR/small/735541v1_ufig1.gif" ALT="Figure 1000"> View larger version (24K): org.highwire.dtl.DTLVardef@15d4cborg.highwire.dtl.DTLVardef@14591d6org.highwire.dtl.DTLVardef@69990dorg.highwire.dtl.DTLVardef@bf5e23_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: bulk RNA-seq
- research focus: gene regulatory network inference
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- SMAD4 suppresses colitis-associated carcinoma through inhibition of CCL20/CCR6-mediated inflammation
D. N. Hanna, P. Marincola-Smith, … A. L. Means·bioRxiv·May 25, 2022
- Smad4 and TGF-β1 dependent gene expression biomarkers in conditional intestinal adenoma, organoids and colorectal cancer.
M. Surakhy, J. Matheson, … A. B. HASSAN·bioRxiv·Mar 15, 2024
- Aggressive KRAS mutations direct TGF-β response towards partial EMT in patient-derived colorectal cancer tumoroids
Theresia Mair, Philip König, … Gerda Egger·Molecular OncologyPeer-reviewed·Mar 11, 2025
- TCF7L2 Silencing Reprograms the 4D Nucleome of Colorectal Cancer Cells
M. A. Brown, G. A. Dotson, … T. Ried·bioRxiv·May 12, 2020
- SMAD4 Mutation Drives Gut Microbiome Shifts Toward Tumor Progression in Colorectal Cancer
Travis J. Gates, Dechen Wangmo, … Subbaya Subramanian·Discover OncologyPeer-reviewed·Oct 9, 2025
- Gain of Function p53 mutant R273H confers distinct methylation profiles and consequent partial or full EMT states to colon tumour
Harsha Rani, Seemadri Subhadarshini, … Vijayalakshmi Mahadevan·bioRxiv·Jul 3, 2025